Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Treatment Update on BLU-667

Posted: Monday, June 17, 2019

Justin F. Gainor, MD, of Massachusetts General Hospital, provides an update on the activity and safety of the novel RET inhibitor BLU-667 in the treatment of RET fusion–positive non–small cell lung cancer.